Table of Contents

State/Territory Name: Oklahoma

State Plan Amendment (SPA) #: 25-0012

This file contains the following documents in the order listed:

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850

Center for Medicaid and CHIP Services

Medicaid Benefits and Health Programs Group

September 05, 2025

Christina Foss
Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, OK 73105

re: Oklahoma State Plan Amendment (SPA) 25-0012

Dear Christina Foss:

The CMS Division of Pharmacy team has reviewed Oklahoma's SPA 25-0012, received in the CMS Division of Program Operations on July 29, 2025. This amendment proposes to update the applicable date of the new Sovereign States Drug Consortium (SSDC) supplemental rebate agreement.

Based on the information provided and consistent with the regulations at 42 CFR 447.20, we are pleased to inform you OK-25-0012 is approved with an effective date of October 1, 2025. We are attaching a copy of the signed CMS-179 form, as well as the page approved for incorporation into Oklahoma's state plan.

If you have any questions regarding this state plan amendment, please contact Desiree Elekwa Izuakor at 410-786-1077or desiree.elekwaizuakor@cms.hhs.gov.

Sincerely,

[redacted]

Mickey Morgan
Deputy Director, Division of Pharmacy

cc: Heather Cox, Oklahoma Health Care Authority
Kasie McCarty, Oklahoma Health Care Authority
Stacey Steiner, Oklahoma State Lead, CMS
Sean Webster, Oklahoma Health Care Authority

DEPARTMENT OF HEALTH ANDHUMAN SERVICES
CENTERS FOR MEDICARE & MEDICAID SERVICES

FORM APPROVED
OMB No. 0938-0193

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL

FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES

1. TRANSMITTAL NUMBER: 25 — 0012

2. STATE: OK

3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT

TO: CENTER DIRECTOR
CENTERS FOR MEDICAID & CHIP SERVICES
DEPARTMENT OF HEALTH AND HUMAN SERVICES

4. PROPOSED EFFECTIVE DATE
10/01/2025

5. FEDERAL STATUTE/REGULATION CITATION
Section 1927 of the Social Security Act

6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)
a. FFY 2025 $ 0
b. FFY 2026 $ 0

7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT
Attachment 3.1-A, Page 5a-1a

8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT *(If Applicable)*
Attachment 3.1-A, Page 5a-1a; TN # 23-0026

9. SUBJECT OF AMENDMENT
Amending the State Plan to revise the State's Supplemental Rebate Agreement to update the applicable date of the new SSDC rebate agreement.

10. GOVERNOR'S REVIEW *(Check One)*

- ☐ GOVERNOR'S OFFICE REPORTED NO COMMENT
- ☐ COMMENTS OF GOVERNOR'S OFFICE ENCLOSED
- ☐ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL
- ☑ OTHER, AS SPECIFIED:
  The governor's office does not review state plan material.

11. [redacted]ENCY OFFICIAL

12. TYPED NAME
Christina Foss

13. TITLE
State Medicaid Director

14. DATE SUBMITTED
07/29/2025

15. RETURN TO
Oklahoma Health Care Authority
Attn: Christina Foss
4345 N. Lincoln Blvd.
Oklahoma City, OK 73105

cc: Kasie McCarty; Heather Cox; Sean Webster

FOR CMS USE ONLY

16. DATE RECEIVED
07/29/2025

17. DATE APPROVED
09/05/2025

PLAN APPROVED - ONE COPY ATTACHED

18. EFFECTIVE DATE OF APPROVED MATERIAL
10/01/2025

19. [redacted]

20. TYPED NAME OF APPROVING OFFICIAL
Mickey Morgan

21. TITLE OF APPROVING OFFICIAL
Deputy Director, Division of Pharmacy

22. REMARKS

Instructions on Back

AMOUNT, DURATION AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED CATEGORICALLY NEEDY

12a. **Prescribed drugs, dentures, prosthetic devices, and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist** *(continued)*

Tiered Drug List

The DUR Board will determine medical necessity for drugs covered under the Oklahoma tiered drug list and establish criteria for any prior authorization process. A preferred product, tiered drug list is utilized for certain categories of drugs. Drugs included in Tier One are generally available without additional documentation. A prior authorization process is available for drugs not included in Tier One.

Supplemental Drug Rebate

Pursuant to Section 1927 of the Act, the State has the following policies for Medicaid supplemental rebates:

A model agreement between the State and a drug manufacturer for drugs provided to the Medicaid population, submitted to CMS on January 2, 2004, and entitled "State of Oklahoma, Oklahoma Health Care Authority Supplemental Rebate Agreement" and subsequent revisions have been authorized by CMS.

Supplemental rebates received by the State in excess of those required under the national rebate agreement will be shared with CMS on the same percentage basis as applied under the national rebate agreement.

Drugs of manufacturers who do not participate in the supplemental rebate program will still be available to Medicaid recipients.

Beginning January 1, 2017, Oklahoma became part of the Sovereign States Drug Consortium (SSDC). SSDC negotiates supplemental rebates for Oklahoma. The State retains all options to accept or reject offers. Drugs of manufacturers who do not participate in the supplemental rebate program will still be available to Medicaid recipients. The updated SSDC rebate agreement between the State and participating manufacturers for drugs provided to the Medicaid program, submitted to CMS on July 29, 2025, supersedes the SSDC rebate agreement approved in OK SPA 23-0026. CMS has authorized the updated agreement. The updated agreement applies to drugs dispensed effective January 1, 2026.

Products for which a signed Medicaid State Supplemental Rebate Agreement is on file will have preferred status. This status may be reflected in the product's placement in lower tiers of the Tiered Drug List, inclusion on a Preferred Drug List, or by removing a prior authorization requirement from the product.

The State may enter into value-based contracts with manufacturers on a voluntary basis. These contracts will be executed on the model agreement entitled "Value-Based Supplemental Rebate Agreement" submitted to CMS on November 4, 2019 and authorized for use beginning January 1, 2020.